Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutationsTakahiko YasudaMasashi SanadaMasahito KawazuShinya KojimaShinobu TsuzukiHiroo UenoEisuke IwamotoYuka Iijima-YamashitaTomomi Yamada
Therapies for B-ALL have greatly improved since the 1970s when the survival rate was only 10% [11]. Today, at least 90% of paediatric patients and 40% of adult patients will recover from this disease [12]. This treatment success is explained by breakthroughs in understanding the molecular ...
In the majority of pediatric B-ALL cases,leukemia cellsdo not express a B cell receptor (BCR) (Rickert, 2013). However, pediatric B-ALL cases frequently express surface interleukin-7 receptor (IL-7R) and have high levels of JAK-STAT signaling (Buchner et al., 2015). These observations su...
The overall five- and ten-year relative survival rate of the high-risk group were 42.4% and 39.6%, respectively, whereas the corresponding rates in the low-risk group were 79.1% and 61.2%, respectively. Moreover, we found that the LncRS was significantly associated with OS (HR =...
Virtually, all cases have a germinal center B-cell immunophenotype and a high prolife- ration rate. Despite a variety of therapeutic appro- aches that have been used to date, patients with DHL have a poor prognosis with a median overall survival (OS) of o2 years. In daily practice we ...
(Fig.1). Important signaling pathways that are activated include STAT3, NF-κB, ERK1/2, AKT/PI3K, and play an important role in disease progression. New therapies directly target the growth and survival of MM cells which are necessary strategies in high-risk relapsed and refractory (RR) MMs...
Chronic lymphoblastic leukemia CR: Complete response CRS: Cytokine release syndrome DLBCL: Diffuse large B-cell lymphoma HSCT: Hematopoietic stem cell transplantation NHL: Non-Hodgkin lymphoma ORR: Overall response rate OS: Overall survival R/R: ...
3.4B-cell chronic lymphoid leukemia (B-CLL) Echis also closely associated with other rare cancers. B-cell chronic lymphoid leukemia (B-CLL) is a highly heterogeneous humanmalignancy. One of the common features of B-CLL cells is their prolonged survival in peripheral blood, which is due to a...
It was reported that pimozide inhibited the viability of acute myeloid leukemia (AML) cells by promoting the degradation of the USP1 substrate ID1 [13]. We previously found that pimozide prolonged the survival time of t(8;21) AML mice [15]. Therefore, a better understanding of how USP1 ...
antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL). ...